To the Editor: In the November issue of Pediatric Research, Nozu et al (1) published a well-presented case report of the Gitelman syndrome that resulted from inclusion of a cryptic exon in the SLC12A3 mRNA. The 238-nucleotide (nt) cryptic exon (not 283-nt as in Fig. 3 ) was activated by a point mutation that created a new 5Ј-splice site in intron 13. I inspected nt sequence of this intron and found that the cryptic exon was located in the vicinity of an antisense AluY, a young member of the family of short interspersed nuclear elements (SINEs). Among human transposable elements, SINEs are preferentially exonized in human disease genes, particularly their antisense copies (Ref. 2 and references therein). Their exonization is often facilitated by the Alu poly(T) tail that functions as the polypyrimidine tract, a key signal for 3Ј-splice site recognition. However, this was not the case in the reported patient. Instead, the RepeatMasker annotation of this intron revealed that the AluY was inserted in a more ancient repeat termed MER91B (Fig. 1) . The 3Ј portion of this nonautonomous DNA transposon contained a predicted branch point sequence of the cryptic exon and at least part of its polypyrimidine tract. Interestingly, the terminal segment of MER91B diverged to accommodate a stretch of four uninterrupted uracils that were likely to provide an adequate polypyrimidine tract of the new exon.
A search of the database of exonized transposable elements (3) revealed that not less than eight human genes contained MER91B fossils, including those encoding the ␣ subunit of the hypoxia-inducible factor 1 (gene HIF1AN, GenBank accession number NM_017902), mitochondrial glycerol 3-phosphate (GPAM, NM_020918), huntingtin-associated protein 1 (HAP1, NM_003949), a tumor necrosis factor ligand (TNFSF4, NM_003326), GATA binding protein 5 (GATA5, NM_080473), a platelet-derived growth factor beta (PDGFB, NM_002608), a putative protein LOC389384, and the hemochromatosis protein precursor (HFE, NM_139004).
Each of these genes contained this transposon in the 3Ј untranslated region, consistent with multiple stop codons in reading frames of the MER91B consensus. The total length of MER91 fragments in the human transcriptome was ϳ3.5 kb and their average size was 123 nt (SD 45 nt).
This case well illustrates how transposable elements and their combinatorial diversity contribute to cryptic exon activation and genetic disease. Although still rare, these reports are extremely valuable for studying splice-site selection processes and the importance of RNA structure in RNA processing (2) . Such cases will not be limited to Mendelian disorders, but low-inclusion cryptic exons are likely to be present in susceptibility genes for polygenic and complex traits. SINEs and other transposable elements may be particularly apt to fine-tune gene expression levels through this highly versatile mechanism, thus, shaping the phenotypic variability and disease severity. Future reports of cryptic exon activation should, therefore, present repeat annotations of DNA sequences ascertained in patients with genetic disease and/or their family members.
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Response: We highly appreciate the helpful comments of Dr. Vorechovsky, concerning our previous report (1) . He conducted an in silico analysis to clarify the mechanism of intron exonization that was detected in our patient. We have conducted genetic diagnosis for a typical Gitelman syndrome patient, but standard PCR and direct sequencing method for searching all exons and exon-intron boundaries yielded only detection of a heterozygous mutation. As you undoubtedly know, Gitelman syndrome is an autosomal recessive disease so that the method used by us may have missed other heterozygous mutations in this patient. We, therefore, conducted RT-PCR analysis and detected the 238nt cryptic exon between exons 13 and 14 activated by a point mutation, c1670-191CϾT in deep intron 13, which created a new 5Ј splice site. As medical practitioners, we are usually satisfied with such a result as detection of a missing mutation. However, Vorechovsky (2), an authority on analysis of the mechanisms of intronic exonization, conducted an in silico analysis and clarified the mechanism that applied to our patient. He also mentioned that this kind of report concerning cryptic exon activation is still rare and extremely valuable for studying splice-site selection processes and the importance of RNA structure in RNA processing. Reciprocally, I think the kind of analysis conducted by Vorechovsky is both very important and interesting for medical practitioners. We should, therefore, report all patients in whom we have detected such mutations and conduct in silico analyses to clarify the relevant mechanisms. And, if we cannot obtain clarification, we should ask the specialists.
